beta-thalassemia
Drug research and approvals for beta-thalassemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 44 studies of beta-thalassemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, FDA has 4 approved and 10 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 44
- Trials authorized in Canada: 4
- FDA orphan approvals: 4
- EU medicines: 3
- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent…NCT07884773 · Phase 3 · Khyber Medical University Peshawar · starts Oct 12, 2026
- Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemiaNCT07680803 · Phase 2 · Fondazione Telethon · starts Jul 6, 2026
- Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta ThalassemiaNCT07673302 · Not applicable · Riphah International University · starts Jun 20, 2026
- Transfusion-Related Changes in Oxidative Stress Biomarkers in NeonatesNCT07672275 · Not reported · Medical University of Graz · starts Dec 12, 2025
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsNCT07599176 · Phase 1 / Phase 2 · National Heart, Lung, and Blood Institute (NHLBI) · starts Jul 8, 2026
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or…NCT07517133 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Sep 1, 2026
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With…NCT07506863 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Sep 24, 2026
- A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastNCT07215975 · Not reported · Bristol-Myers Squibb · starts Jun 26, 2026
- Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDNCT07207577 · Not applicable · Centre Hospitalier Metropole Savoie · starts Sep 4, 2025
Approved 5
- LuspaterceptTransforming growth factor beta inhibitor
- DeferasiroxIron chelating agent
- Deferiprone
- Betibeglogene autotemcelHemoglobin beta chain exogenous gene
- Exagamglogene autotemcelB-cell lymphoma/leukemia 11A gene editing negative modulator
Phase 3 5
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- MitapivatPyruvate kinase isozymes R/L activator
- SildenafilPhosphodiesterase 5A inhibitor
- DeferoxamineIron chelating agent
- Blood cells, red
Phase 2 12 of 21
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- Fludarabine
- Dimebutic acid
- Vamifeport
- BusulfanDNA inhibitor
- MetoprololBeta-1 adrenergic receptor antagonist
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- Epoetin alfaErythropoietin receptor agonist
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
Phase 1 or earlier 11
- CyclosporineCyclophilin A modulator
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- BriquilimabStem cell growth factor receptor inhibitor
- AcetylcysteineGlutathione precursor
- Deferitrin
- N-monoacetylcystine
- Sapablursen sodium
- Renizgamglogene autogedtemcel
How its trials ended
288 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 45 whose ending is known, 44% met their primary endpoint, 2% missed it and 53% stopped early.
- Completed, result not reported10135%
- Ongoing8931%
- Status unknown5318%
- Met its primary endpoint207%
- Stopped: other or unclear93%
- Stopped: enrollment or feasibility72%
- Stopped: lack of efficacy41%
- Stopped: sponsor or business decision41%
- Missed its primary endpoint1<1%
| Nov 13, 2019 | A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of isis 702843 administered…Isis 702843 (IONIS-TMPRSS6-LRX) | Ionis Pharmaceuticals | Closed |
| Jul 15, 2019 | A phase 1b sequential open label dose ranging study of safety, pharmacokinetics, and preliminary activity of benserazide in subjects with beta thalassemia…Benserazide | Phoenicia Biosciences Inc. | Pending |
| Mar 5, 2019 | A long-term follow-up study of subjects with beta-thalassemia or sickle cell disease treated with autologous CRISPR-CAS9 modified hematopoietic stem cells…CTX001 / Busulfan / Plerixafor | Vertex Pharmaceuticals | Ongoing |
| Feb 25, 2019 | A phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept(ACE-536) clinical trialsLuspatercept (ACE-536) | Bristol-Myers Squibb | Ongoing |
| Jul 1, 2026 | CasgevyTreatment of patients aged 2 years and older with transfusion-dependent beta-thalassemia (TDT) | Vertex Pharmaceuticals Inc. | Approved |
| Dec 23, 2025 | AqvesmeTreatment of anemia in adults with alpha- or beta-thalassemia | Agios Pharmaceuticals, Inc. | Approved |
| Jan 16, 2024 | CasgevyTreatment of patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT) | Vertex Pharmaceuticals Inc. | Approved |
| Aug 17, 2022 | ZyntegloTreatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions | Genetix Biotherapeutics Inc. | Approved |
| Nov 4, 2025 | DesidustatTreatment of beta-thalassemia | Zydus Lifesciences Limited | Designated |
| Jul 11, 2024 | Genetically modified CD34+ hematopoietic stem cells using a…Treatment of beta-thalassemia | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Designated |
| Oct 15, 2020 | Synthetic 2?-O-(2-methoxyethyl)-modified antisense…Treatment of beta-thalassemia | Ionis Pharmaceuticals, Inc. | Designated |
| Jun 17, 2019 | 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluo…Treatment of beta-thalassemia | Vifor Pharma, Inc. | Designated |
| Jun 4, 2019 | Autologous CD34+ hematopoietic stem and progenitor cells…Treatment of beta-thalassemia | Sangamo Therapeutics, Inc. | Designated |
| Jun 21, 2016 | SirolimusTreatment of beta-thalassemia. | Rare Partners srl Impresa Sociale | Designated |
| Jan 11, 2006 | Lentiviral vector encoded with a human beta-globin gene…Treatment of beta-thalassemia major and beta-thalassemia intermedia | San Rocco Therapeutics, LLC | Designated |
| Dec 21, 1998 | Deferoxamine starch conjugateTreatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia. | Biomedical Frontiers, Inc. | Designated |
| Dec 18, 1992 | IsobutyramideTreatment of beta-hemoglobinopathies and beta-thalassemia syndromes. | Perrine, Susan P., M.D. | Designated |
| Apr 7, 1992 | Arginine butyrateTreatment of beta-hemoglobinopathies and beta-thalassemia. | Perrine, Susan P., M.D. | Designated |
| Feb 9, 2024 | CasgevyExagamglogene autotemcel · orphan | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Aug 28, 2006 | ExjadeDeferasirox | Novartis Europharm Limited | EMA ↗ |
| Aug 25, 1999 | FerriproxDeferiprone | Chiesi Farmaceutici S.p.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA